Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.BI 765064 SIRP α-antibody Phase I started
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRP α Antagonist Monoclonal Antibody,
BI 765063, in Patients with Advanced Solid TumorsFirst-in-class checkpoint inhibitor BI 765063 licensed to and being developed under a collaboration agreement between Boehringer Ingelheim and OSE ImmunotherapeuticsClinical Trial Authorization and dosing of the first patient triggers a total of €15 million milestone payments from Boehringer Ingelheim to OSE Immunotherapeutics (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 17, 2019 Category: Research Source Type: news
Winners of BVDzero Scholarship Programme
Boehringer Ingelheim announces winners of BVDzero Scholarship ProgrammeThe aim of this initiative is to increase bovine viral diarrhoea (BVD) awareness among veterinary studentsThis programme has been implemented in collaboration with the World Association for Buiatrics, as an incentive to participate in the World Buiatrics Congress 2020 in Madrid (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 14, 2019 Category: Research Source Type: news
Boehringer Ingelheim relies on digital transformation
The healthcare of tomorrow:
Boehringer Ingelheim relies on digital transformationDigital Health makes the treatment, prevention, and early detection of diseases faster and more preciseHealthcare solutions of the future were discussed at the re:publica digital conferenceBoehringer Ingelheim calls for improved framework conditions for digitalization in the healthcare industry (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 11, 2019 Category: Research Source Type: news
Boehringer Ingelheim extends PROTAC Discovery Program
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer AllianceBoehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicinesResults published in Nature Chemical Biology showcase the use of the broadly applicable structure-based PROTAC design approach to discover highly potent and selective drug candidatesThe first PROTAC is made freely available via Boehringer Ingelheim ’s open innovation portal, opnMeStructure-based PROTAC design promises to accelerate the development ...
Source: Boehringer Ingelheim Corporate News - June 11, 2019 Category: Research Source Type: news
CAROLINA-full-data
Full data from CAROLINA ® outcome trial support long-term cardiovascular safety profile of Trajenta®CAROLINA ® demonstrated no increased cardiovascular risk for Trajenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor Adults with diabetes treated with Trajenta ® experienced significantly fewer events of hypoglycaemia and a modest weight reduction compared to patients treated with glimepiride Detailed results from CAROLINA ® were presented at the American Diabetes Association’s 79th Scientific Sessions (Source: Boehringer...
Source: Boehringer Ingelheim Corporate News - June 11, 2019 Category: Research Source Type: news
type-2-diabetes-cardiorenal-post-hoc-analysis
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuriaFindings from a post-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and chronic kidney disease without overt proteinuria were presented at the 79th American Diabetes Association Scientific Sessions® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 10, 2019 Category: Research Source Type: news
Partnering with Constantia Flexibles for augmented reality packaging experience
Boehringer Ingelheim partners with Constantia Flexibles to provide augmented reality packaging experienceThe packaging of Nutraxin, a nutritional supplement for horses, is now equipped with augmented reality and interactive featuresThis partnership reaffirms Boehringer Ingelheim ’s continuous focus on providing innovative solutions to its customers (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 4, 2019 Category: Research Source Type: news
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch digital healthcare program in KenyaNew digital disease management program “Tiba Yako” breaks access and awareness barriers in hypertension and diabetes careThe mobile-based technology allows patients to monitor their blood pressure and blood glucose levels at home, digitally sending the results to their doctor Tiba Yako is an integrated disease service model that will offer benefits to patients, healthcare providers and payers alike There is an unmet need for efficient affordable and widely accessible care for hypertension and diabetes in Kenya1,2 (Source: Boehringer...
Source: Boehringer Ingelheim Corporate News - June 3, 2019 Category: Research Source Type: news
Boehringer Ingelheim_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch digital healthcare program in KenyaNew digital disease management program “Tiba Yako” breaks access and awareness barriers in hypertension and diabetes careThe mobile-based technology allows patients to monitor their blood pressure and blood glucose levels at home, digitally sending the results to their doctor Tiba Yako is an integrated disease service model that will offer benefits to patients, healthcare providers and payers alike There is an unmet need for efficient affordable and widely accessible care for hypertension and diabetes in Kenya1,2 (Source: Boehringer...
Source: Boehringer Ingelheim Corporate News - June 3, 2019 Category: Research Source Type: news
New collaboration with Gubra on obesity treatment
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonistsObesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options availableNew collaboration aims to develop novel peptide poly-agonists for the treatment of obesity and concomitant diseasesGubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 29, 2019 Category: Research Source Type: news
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platformIt is the first comprehensive ‘industry-academia-research’ exchange platform jointly set up by an agricultural research institute and a multinational animal health company in ChinaPartners join forces to foster the integration of the industry, academia and research (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 22, 2019 Category: Research Source Type: news
Network-of-1500-stroke-ready-clinics-across-Europe
Network of 1,500 stroke-ready clinics across Europe The award-winning Angels Initiative delivers on its three-year goal to create a network of more than 1,500 stroke-ready clinics across EuropeSince 2016, a total of 2,700 clinics worldwide are now part of the Angels InitiativeThe ESO Angels Awards praise 331 clinics in several countries who have made great steps in optimising stroke care for patients locally (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 22, 2019 Category: Research Source Type: news
nintedanib slows pulmonary function loss in people with ssc-ild
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1Results of pivotal Phase III SENSCIS ®trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USAInterstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3FDA grants priority review to application for regulatory approval for nintedanib in patients with system...
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news
Veterinary oncology experts meet in Germany
Veterinary oncology experts from Europe, Japan and the US meet in GermanyVeterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, GermanyThe collaboration between Boehringer Ingelheim and the Veterinary Oncology Advisory Board focuses on developing unparalleled therapeutic solutions for the veterinary community and establishing new standards of care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news
NOAC-vs-ASA-in-ESUS-trial-results-published-in-NEJM
Trial results of Pradaxa ® vs ASA in ESUS published in NEJMFirst Phase III randomised clinical trial to compare dabigatran etexilate and acetylsalicylic acid (ASA) No significant difference in recurrent stroke prevention after ESUSDabigatran showed no significant difference in major bleeding (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 16, 2019 Category: Research Source Type: news
